세계의 TCR 요법 시장 : 적응증별, 표적 항원별, 주요 기업별, 주요 지역별-업계 동향 및 예측(-2035년)

Global TCR Therapy Market by Target Indication, Target Antigen, Key Players and Key Geographies : Industry Trends and Global Forecasts, Till 2035

US $ 4,799 ￦ 6,565,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,999 ￦ 9,575,000

PDF (One-Location Site License)

PDF 보고서를 동일 사업장의 특정 사업 부문에 속한 모든 분들이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,599 ￦ 14,500,000

PDF (Department License)

PDF 보고서를 부서 단위로 12명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 17,999 ￦ 24,624,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계의 TCR 요법 시장 규모는 2035년까지 예측 기간 동안 51%의 연평균 복합 성장률(CAGR)로 확대될 전망이며, 현재 3,000만 달러에서 2035년까지 41억 3,000만 달러로 성장할 것으로 예측됩니다.

암은 제약 업계에서 연구 및 의약품 개발의 주요 분야 중 하나로 계속되고 있습니다. 실제로 지난 몇 년동안 USFDA는 다양한 유형의 암 치료제로 70여 가지 의약품을 승인했습니다. 비특이성, 소화기계 및 심혈관계에 대한 독성을 비롯한 여러 부작용 등 기존의 치료법과 관련된 과제를 고려하여 의약품 개발자는 표적 항암제 치료를 적극적으로 연구하고 있습니다. 그 중에서 변형 T세포 수용체(TCR)를 이용한 치료법이 유망한 옵션으로 부상하고 있습니다. TCR 요법은 특정 종양 마커를 표적으로 하는 유전자 변형 림프구를 이용합니다. TCR 요법은 치료 관련 부작용을 최소화하면서 숙주 체내에서 종양 세포를 선택적으로 표적화하고 제거하는 것으로 입증되었습니다. 주목해야할 것은 지난 10년간 TCR 요법과 관련된 110개 이상의 임상시험이 등록되었으며, 이는 연구가 활발히 이루어지고 있음을 보여줍니다. 유망한 개발 파이프라인과 유망한 임상시험 결과에 힘입어 TCR 기반 치료 시장은 중장기적으로 큰 성장을 이룰 가능성이 높습니다.

현재 100개가 넘는 업계 및 비업계 기업이 다양한 암 및 비암 질환 치료에 대한 190개 이상의 TCR 기반 면역요법의 가능성을 평가했습니다.

지난 10년간 TCR을 기반으로 하는 치료법을 평가하기 위해 다양한 지역에서 110개 가까이의 임상시험이 등록되었습니다. 현재, 60명 가까운 유명 대학의 과학자들이 TCR 요법의 임상 개발에 종사하고 있으며, 이러한 KOL의 대부분은 주로 미국과 중국에 본사를 두고 있습니다.

본 보고서는 세계의 TCR 요법 시장에 대해 조사했으며, 시장 개요와 함께 적응증별, 표적 항원별, 주요 기업별, 지역별 동향, 시장 진출기업 프로파일 등의 정보를 제공합니다.

목차

제1장 서문

제2장 주요 요약

제3장 서문

제4장 TCR 요법 : 시장 상황

제5장 일반적인 표적 항원 분석

제6장 임상시험 분석

제7장 KOL(Key Opinion Leader)

제8장 TCR 기반 치료 프로파일

• 장의 개요
• Kimmtrak(R)/IMCgp100/Tebentafusp(Immunocore)
• GSK3377794/NY-ESO-1C259 T-cells/Letetresgene Autoleucel(GlaxoSmithKline)
• ADP-A2M4/Afamitresgene Autoleucel/Afami-cel(Adaptimmune Therapeutics)
• JTCR016(Juno Therapeutics)
• TBI-1301(Takara Bio)
• MDG1011(Medigene)

제9장 파트너십 및 협업

제10장 자금 조달 및 투자 분석

제11장 특허 분석

제12장 사례 연구 : 세포 치료의 제조

제13장 원가 분석

제14장 시장 예측 및 기회 분석

제15장 프로모션 분석

제16장 기업 프로파일

• 장의 개요
• Adaptimmune Therapeutics
• Alaunos Therapeutics
• Bluebird Bio
• Bristol Myers Squibb
• Cellular Biomedicine Group
• Gilead Sciences
• GlaxoSmithKline
• Immatics
• Immunocore
• Lion TCR
• Takara Bio
• Zelluna immunotherapy

제17장 결론

제18장 주요 인사이트

제19장 부록 1 : 테이블 형식의 데이터

제20장 부록 2 : 기업 및 단체 일람

AJY

영문 목차

영문목차

GLOBAL TCR THERAPY MARKET: OVERVIEW

As per Roots Analysis, the global TCR therapy market is estimated to grow from USD 0.03 billion in the current year to USD 4.13 billion by 2035, at a CAGR of 51% during the forecast period, till 2035.

The market sizing and opportunity analysis has been segmented across the following parameters:

Target Indications

• Nasopharyngeal Carcinoma
• Multiple Myeloma
• Head and Neck Carcinoma
• Sarcoma
• Melanoma
• Acute Myeloid Leukemia
• Lung Cancer
• Ovarian Cancer
• Merkel Cell Cancer

Target Antigens

• NY-ESO-1
• EBV
• gp100

Key Players

• GlaxoSmithKline
• China Immunotech
• Xinqiao Hospital of Chongqing
• TCRCure Biopharma
• Adaptimmune Therapeutics
• Immunocore
• Intellia Therapeutics
• Takara Bio
• bluebird bio

Key Geographical Regions

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and North Africa
• Rest of the World

GLOBAL TCR THERAPY MARKET: GROWTH AND TRENDS

Cancer continues to be one of the key areas of research and drug development within the pharmaceutical industry. In fact, in the past few years, the USFDA has approved more than 70 drugs for the treatment of different types of cancer. Given the challenges associated with conventional therapies, such as non-specificity and several side effects including gastrointestinal and cardiovascular toxicities, drug developers are actively investigating targeted anti-cancer therapies. Of these, modified T-cell receptor (TCR) based therapies have emerged as a promising option. TCR therapy utilizes genetically modified lymphocytes to target specific tumor markers. TCR therapies have been demonstrated to selectively target and eliminate tumor cells from the body of a host with minimal treatment-related side effects. Notably, over 110 clinical trials related to TCR therapies have been registered in the past ten years, indicating substantial research activity. Driven by a promising development pipeline and encouraging clinical trial results, the TCR-based therapy market is likely to witness significant growth in the mid to long-term.

GLOBAL TCR THERAPY MARKET: KEY INSIGHTS

The report delves into the current state of the global TCR therapy market and identifies potential growth opportunities within the industry. Some key findings from the report include:

1. More than 100 industry and non-industry players are currently evaluating the potential of over 190 TCR-based immunotherapies for the treatment of various oncological and non-oncological disorders.

2. More than 90% of the therapy candidates, which are being developed to target a wide range of disease indications are autologous in nature; NY-ESO-1 and MAGE have emerged as the most popular target antigens.

3. In the last 10 years, close to 110 clinical trials have been registered across different geographies for the evaluation of TCR-based therapies; extensive efforts are underway to improve the successive generations of such therapies.

4. Close to 60 scientists from renowned universities are presently involved in the clinical development of TCR-based therapies; majority of these KOLs are primarily based in the US and China.

5. Close to 200 players claim to have the required capabilities to manufacture different types of cell therapies; such firms also offer a wide range of services across different stages of product development.

6. A growing interest in this field is reflected from the increase in the partnership activity, involving both international and indigenous stakeholders; majority of the such deals were signed between players based in North America.

7. Several investors, having realized the opportunity within this upcoming segment of T-cell immunotherapy, have invested USD 11 billion, across 140 instances.

8. More than 75 patents have been filed / granted by various stakeholders in order to protect the intellectual property generated within this field.

9. With a growing focus on the development pipeline and encouraging clinical results, the market is anticipated to witness an annualized growth rate of 51%, in the next decade.

GLOBAL TCR THERAPY MARKET: KEY SEGMENTS

Currently, Multiple Myeloma Segment Occupies the Largest Share of the Global TCR Therapy Market

Based on target indication, the market is segmented into nasopharyngeal carcinoma, multiple myeloma, head and neck carcinoma, sarcoma, melanoma, acute myeloid leukemia, lung cancer, ovarian cancer and Merkel cell cancer. At present, the multiple myeloma segment holds the maximum share of the global TCR therapy market. It is worth highlighting that the TCR therapy market for nasopharyngeal carcinoma is likely to drive the market in the near future.

NY-ESO-1 Target Antigen is Likely to Dominate the Global TCR Therapy Market During the Forecast Period

Based on the target antigen, the market is segmented into NY-ESO-1, EBV and gp100. Currently, NY-ESO-1 antigen holds the maximum share within the TCR therapy market. This trend is unlikely to change in the near future.

North America Accounts for the Largest Share of the Market

Based on the key geographical regions, the market is segmented into North America, Europe, Asia-Pacific, Middle East and North Africa, Latin America, and the Rest of the world. Majority share is expected to be captured by drug developers based in North America and Europe. It is worth highlighting that, over the years, the market in Asia-Pacific is expected to grow at a higher CAGR.

Example Players in the Global TCR Therapy Market

• Adaptimmune Therapeutics
• Alaunos Therapeutics
• Bristol Myers Squibb
• Cellular Biomedicine
• Gilead Biosciences
• GlaxoSmithKline
• Immatics
• Immunocore
• Lion TCR
• Takara Bio
• Zelluna Immunotherapy

Primary Research Overview

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:

• Vice President, Immuno-Oncology, Celyad
• Vice President, Scientific Affairs, Kite Pharma
• Co-Founder and Chief Executive Officer, Lion TCR
• Chief Operating Officer, TxCell

GLOBAL TCR THERAPY MARKET: RESEARCH COVERAGE

• Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the global TCR therapy market, focusing on key market segments, including [A] target indications, [B] target antigen, [C] key players and [D] geographical regions.
• Market Landscape: A comprehensive evaluation of TCR therapies, considering various parameters, such as [A] type of developer, [B] phase of development, [C] therapeutic area, [D] key target indication, [E] key target antigen, [F] source of T-cells, [G] route of administration, [H] dosing frequency, [I] target patient segment, [J] type of therapy and [K] most active players (in terms of number of TCR therapies). In addition, the chapter provides details on developer landscape of the industry and non-industry players.
• Popular Target Antigen Analysis: An in-depth analysis of popular target antigens, based on the number of TCR therapies that are being developed for a particular type of antigen by various industry stakeholders to identify potential targets.
• Clinical Trial Analysis: Examination of completed, ongoing, and planned clinical studies of various t-cell receptor therapies based on parameters like [A] trial registration year, [B] enrolled patient population, [C] trial status, [D] trial phase, [E] target patient segment, [F] type of sponsor / collaborator, [G] most active players (in terms of number of registered trials), [H] key focus areas and [I] geography.
• Key Opinion Leader Analysis: An in-depth examination that emphasizes the key opinion leaders (KOLs) within this field includes an evaluation of various principal investigators overseeing clinical trials associated with TCR therapies. In addition, the chapter highlights the most prominent KOLs, based on our proprietary and third-party scoring criteria.
• Drug Profiles: In-depth profiles of marketed and mid- to late-stage clinical products (phase I/II or above), focusing on [A] overview of the therapy, [B] its mechanism of action, [C] dosage information, [D] details on the cost and sales information (wherever available), [E] a clinical development plan, and [F] clinical trial results.
• Company Profiles: In-depth profiles of key industry players in TCR therapies market, focusing on [A] company overviews, [B] product portfolio, [C] technology portfolio (if available), [D] strategic / venture capital investments made in these companies, [E] an insightful recent development related to TCR therapies, and [F] future outlook.
• Partnerships and Collaborations: An analysis of partnerships established in this sector, covering R&D agreements, license agreements (specific to technology platforms and product candidates), product development and commercialization agreements, manufacturing agreements, clinical trial collaborations, product supply management agreements, joint ventures, and others.
• Funding and Investment Analysis: A detailed evaluation of the investments made into the companies having proprietary T-cell receptor candidates / technologies, encompassing seed financing, venture capital financing, capital raised from IPOs and subsequent offerings, grants, and debt financing.
• Patent Analysis: Detailed analysis of various patents filed / granted related to TCR therapies based on [A] type of patent, [B] patent publication year, [C] geographical distribution, [D] Cooperative Patent Classification (CPC) symbols, [E] emerging focus area, [F] type of player, [G] leading player (in terms of number of patents), and [H] patent benchmarking. It also includes a detailed valuation analysis.
• Case Study: A case study on manufacturing cell therapy products, highlighting the key challenges, and a detailed list of contract service providers and in-house manufacturers involved in this space.
• Cost Price Analysis: A comprehensive discussion on the various factors that are likely to influence the pricing of cell-based therapies. This includes an exploration of different models and approaches that pharmaceutical companies may consider while determining the prices of their lead therapy candidates that are likely to be marketed in the near future.
• Promotional Analysis: A review of the key promotional strategies that are being implemented by the developers of the approved TCR therapy (Kimmtrak(R)).

KEY QUESTIONS ANSWERED IN THIS REPORT

• How many companies are currently engaged in this market?
• Which are the leading companies in this market?
• What kind of partnership models are commonly adopted by industry stakeholders?
• What factors are likely to influence the evolution of this market?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

• Complimentary PPT Insights Packs
• Complimentary Excel Data Packs for all Analytical Modules in the Report
• 10% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

• 1.1. Chapter Overview
• 1.2. Market Segmentations
• 1.3. Research Methodology
• 1.4. Key Questions Answered
• 1.5. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

• 3.1. Chapter Overview
• 3.2. Pillars of Cancer Therapy
• 3.3. Overview of Immunotherapies
• 3.4. Fundamentals of Cancer Immunotherapy
• 3.5. Classification of Cancer Immunotherapies
  • 3.5.1. By Mechanism of Action
    • 3.5.1.1. Active Immunotherapy
    • 3.5.1.2. Passive Immunotherapy
  • 3.5.2. By Type of Target
  • 3.5.3. By Approach
    • 3.5.3.1. Activation and Suppression Immunotherapy
  • 3.5.4. By Product Class
    • 3.5.4.1. Monoclonal Antibodies
    • 3.5.4.2. Bispecific Antibodies
    • 3.5.4.3. Cytokines
    • 3.5.4.4. Oncolytic Virus Therapy
    • 3.5.4.5. Therapeutic Cancer Vaccines
    • 3.5.4.6. Cell-based Therapies
• 3.6. T-Cell Immunotherapies
  • 3.6.1. Historical Evolution
  • 3.6.2. Key Considerations for Developing T-Cell Immunotherapies
  • 3.6.3. Strategies Employed for the Redirection of T-Cells
  • 3.6.4. Manufacturing of Engineered T-Cells
  • 3.6.5. T-Cell Transduction and Transfection Methods
    • 3.6.5.1. Retroviral Vectors
    • 3.6.5.2. Lentiviral Vectors
    • 3.6.5.3. Non-viral Transfection Methods
• 3.7. T-Cell Receptor (TCR)-based Cell Therapy
  • 3.7.1. Development History
  • 3.7.2. Anatomical Layout of TCR
  • 3.7.3. Development of TCR Therapy
  • 3.7.4. Differences between CAR-T and TCR-based Therapies
• 3.8. Concluding Remarks

4. TCR-BASED THERAPIES: MARKET LANDSCAPE

• 4.1. Chapter Overview
• 4.2. TCR-based Therapies: Overall Market Landscape
  • 4.2.1. Analysis by Type of Developer
  • 4.2.2. Analysis by Phase of Development
  • 4.2.3. Analysis by Therapeutic Area
  • 4.2.4. Analysis by Phase of Development and Therapeutic Area
  • 4.2.5. Analysis by Key Target Indication
  • 4.2.6. Analysis by Key Target Antigen
  • 4.2.7. Analysis by Source of T-Cells
  • 4.2.8. Analysis by Route of Administration
  • 4.2.9. Analysis by Phase of Development and Route of Administration
  • 4.2.10. Analysis by Dosing Frequency
  • 4.2.11. Analysis by Target Patient Segment
  • 4.2.12. Analysis by Type of Therapy
  • 4.2.13. Analysis by Phase of Development and Type of Therapy
  • 4.2.14. Most Active Industry Players: Analysis by Number of TCR-based Therapies
  • 4.2.15. Most Active Non-Industry Players: Analysis by Number of TCR-based Therapies
• 4.3. TCR-based Therapies: Overall Developer Landscape
  • 4.3.1. Analysis by Year of Establishment
  • 4.3.2. Analysis by Company Size
  • 4.3.3. Analysis by Location of Headquarters

5. POPULAR TARGET ANTIGEN ANALYSIS

• 5.1. Chapter Overview
• 5.2. TCR-based Therapies: Popular Target Antigens of TCR-based Therapies
  • 5.2.1. Popular Targets Related to Hematological Malignancies
  • 5.2.2. Popular Targets Related to Solid Tumors

6. CLINICAL TRIAL ANALYSIS

• 6.1. Chapter Overview
• 6.2. Scope and Methodology
• 6.3. TCR-based Therapies: Clinical Trial Analysis
  • 6.3.1. Analysis by Trial Registration Year
  • 6.3.2. Analysis by Trial Registration Year and Enrolled Patient Population
  • 6.3.3. Analysis by Trial Status
  • 6.3.4. Analysis by Trial Registration Year and Trial Status
  • 6.3.5. Analysis by Trial Phase
  • 6.3.6. Analysis of Enrolled Patient Population by Trial Phase
  • 6.3.7. Analysis by Target Patient Segment
  • 6.3.8. Analysis by Type of Sponsor / Collaborator
  • 6.3.9. Analysis by Study Design
  • 6.3.10. Most Active Industry Players: Analysis by Number of Registered Trials
  • 6.3.11. Most Active Non-Industry Players: Analysis by Number of Registered Trials
  • 6.3.12. Word Cloud: Key Focus Areas
  • 6.3.13. Analysis of Clinical Trials by Geography
  • 6.3.14. Analysis of Enrolled Patient Population by Geography

7. KEY OPINION LEADERS

• 7.1. Chapter Overview
• 7.2. Assumptions and Key Parameters
• 7.3. Methodology
• 7.4. TCR-based Therapies: Key Opinion Leaders
  • 7.4.1. Analysis by Type of Organization
  • 7.4.2. Analysis by Affiliated Organization
  • 7.4.3. Analysis by Qualification
  • 7.4.4. Analysis by Geographical Location of KOLs
  • 7.4.5. KOL Activeness versus KOL Strength
  • 7.4.6. Most Prominent KOLs: Analysis by RA score
  • 7.4.7. Most Prominent KOLs: Comparison of RA Score and Third-Party Score

8. TCR-BASED THERAPY PROFILES

• 8.1. Chapter Overview
• 8.2. Kimmtrak(R) / IMCgp100 / Tebentafusp (Immunocore)
  • 8.2.1. Therapy Overview
  • 8.2.2. Clinical Trial Information
  • 8.2.3. Clinical Trial Endpoints
  • 8.2.4. Clinical Trial Results
  • 8.2.5. Estimated Sales Revenues
• 8.3. GSK3377794 / NY-ESO-1C259 T-cells / Letetresgene Autoleucel (GlaxoSmithKline)
  • 8.3.1. Therapy Overview
  • 8.3.2. Clinical Trial Information
  • 8.3.3. Clinical Trial Endpoints
  • 8.3.4. Clinical Trial Results
  • 8.3.5. Estimated Sales Revenues
• 8.4. ADP-A2M4 / Afamitresgene Autoleucel / Afami-cel (Adaptimmune Therapeutics)
  • 8.4.1. Therapy Overview
  • 8.4.2. Clinical Trial Information
  • 8.4.3. Clinical Trial Endpoints
  • 8.4.4. Clinical Trial Results
  • 8.4.5. Estimated Sales Revenues
• 8.5. JTCR016 (Juno Therapeutics)
  • 8.5.1. Therapy Overview
  • 8.5.2. Clinical Trial Information
  • 8.5.3. Clinical Trial Endpoints
• 8.6. TBI-1301 (Takara Bio)
  • 8.6.1. Therapy Overview
  • 8.6.2. Clinical Trial Information
  • 8.6.3. Clinical Trial Endpoints
  • 8.6.4. Clinical Trial Results
  • 8.6.5. Estimated Sales Revenues
• 8.7. MDG1011 (Medigene)
  • 8.7.1. Therapy Overview
  • 8.7.2. Clinical Trial Information
  • 8.7.3. Clinical Trial Endpoints
  • 8.7.4. Clinical Trial Results

9. PARTNERSHIPS AND COLLABORATIONS

• 9.1. Chapter Overview
• 9.2. Partnership Models
• 9.3. TCR-based Therapies: Partnerships and Collaborations
  • 9.3.1. Analysis by Year of Partnership
  • 9.3.2. Analysis by Type of Partnership
  • 9.3.3. Analysis by Year of Partnership and Type of Partnership
  • 9.3.4. Analysis by Type of Partner
  • 9.3.5. Most Popular Products: Analysis by Number of Partnerships
  • 9.3.6. Most Active Industry Players: Analysis by Number of Partnerships
  • 9.3.7. Most Active Non-Industry Players: Analysis by Number of Partnerships
  • 9.3.8. Analysis by Geography
    • 9.3.8.1. Intercontinental and Intracontinental Deals
    • 9.3.8.2. International and Local Deals

10. FUNDING AND INVESTMENT ANALYSIS

• 10.1. Chapter Overview
• 10.2. Types of Funding
• 10.3. TCR-based Therapies: Funding and Investment Analysis
  • 10.3.1. Analysis of Instances by Year
  • 10.3.2. Analysis of Amount Invested by Year
  • 10.3.3. Analysis by Type of Funding
  • 10.3.4. Analysis by Type of Investor
  • 10.3.5. Most Active Players: Analysis by Number of Instances
  • 10.3.6. Most Active Investors: Analysis by Amount Invested
  • 10.3.7. Analysis of Amount Invested by Geography
  • 10.3.8. Most Active Investors: Analysis by Number of Funding Instances

11. PATENT ANALYSIS

• 11.1. Chapter Overview
• 11.2. Scope and Methodology
• 11.3. TCR-based Therapies: Patent Analysis
  • 11.3.1. Analysis by Patent Publication Year
  • 11.3.2. Analysis By Patent Application Year
  • 11.3.3. Analysis by Geography
  • 11.3.4. Analysis by Type of Player
  • 11.3.5. Analysis by CPC Symbols
  • 11.3.6. Analysis by Key Focus Area
  • 11.3.7. Leading Player: Analysis by Number of Patents
  • 11.3.8. TCR-based Therapies: Patent Benchmarking
  • 11.3.9. Analysis By Patent Characteristics
  • 11.3.10. TCR-based Therapies: Patent Valuation

12. CASE STUDY: CELL THERAPY MANUFACTURING

• 12.1. Chapter Overview
• 12.2. Overview of Cell Therapy Manufacturing
• 12.3. Cell Therapy Manufacturing Models
  • 12.3.1. Centralized Manufacturing Model
  • 12.3.2. Decentralized Manufacturing Model
• 12.4. Scalability of Cell Therapy Manufacturing Processes
  • 12.4.1. Scale-Up
  • 12.4.2. Scale-Out
• 12.5. Types of Cell Therapy Manufacturers
• 12.6. Key Challenges Related to Manufacturing of Cell Therapies
• 12.7. Important Factors for Cell Therapy Manufacturing
  • 12.7.1. Characterization
  • 12.7.2. Cost of Goods
• 12.8. Automation of Cell Therapy Manufacturing Processes
• 12.9. Cell Therapy Manufacturing Supply Chain
• 12.10. Comparison of Player Having In-House Capabilities and Contract Manufacturers
• 12.11. Regulatory Landscape
• 12.12. Future Perspectives

13. COST PRICE ANALYSIS

• 13.1. Chapter Overview
• 13.2. Factors Contributing to the High Price of Cell / Gene Therapies
• 13.3. Pricing Models for T-Cell Immunotherapies
  • 13.3.1. Based on Associated Costs
  • 13.3.2. Based on Availability of Competing Products
  • 13.3.3. Based on Patient Segment
  • 13.3.4. Based on Opinions of Industry Experts
• 13.4. Reimbursement related Considerations for T-cell Immunotherapies

14. MARKET FORECAST AND OPPORTUNITY ANALYSIS

• 14.1. Chapter Overview
• 14.2. Scope and Limitations
• 14.3. Key Assumptions and Forecast Methodology
• 14.4. Global TCR-based Therapies Market, till 2035
  • 14.4.1. TCR-based Therapies Market: Distribution by Target Indication
  • 14.4.2. TCR-based Therapies Market: Distribution by Target Antigen
  • 14.4.3. TCR-based Therapies Market: Distribution by Key Players
  • 14.4.4. TCR-based Therapies Market: Distribution by Geography
  • 14.4.5. Product Wise Sales Forecast
    • 14.4.5.1. Kimmtrak(R) (IMCgp100 / Tebentafusp) (Immunocore)
      • 14.4.5.1.1. Sales Forecast (USD Million)
      • 14.4.5.1.2. Net Present Value (USD Million)
      • 14.4.5.1.3. Value Creation Analysis
    • 14.4.5.2. GSK3377794 (GlaxoSmithKline)
      • 14.4.5.2.1. Sales Forecast (USD Million)
      • 14.4.5.2.2. Net Present Value (USD Million)
      • 14.4.5.2.3. Value Creation Analysis
    • 14.4.5.3. YT-E001 (China Immunotech)
      • 14.4.5.3.1. Sales Forecast (USD Million)
      • 14.4.5.3.2. Net Present Value (USD Million)
      • 14.4.5.3.3. Value Creation Analysis
    • 14.4.5.4. ADP-A2M4 / Afamitresgene Autoleucel / Afami-cel (Adaptimmune Therapeutics)
      • 14.4.5.4.1. Sales Forecast (USD Million)
      • 14.4.5.4.2. Net Present Value (USD Million)
      • 14.4.5.4.3. Value Creation Analysis
    • 14.4.5.5. EBV-specific TCR-T cell with Anti-PD1 Aauto-secreted Element (TCRCure Biopharma)
      • 14.4.5.5.1. Sales Forecast (USD Million)
      • 14.4.5.5.2. Net Present Value (USD Million)
      • 14.4.5.5.3. Value Creation Analysis
    • 14.4.5.6. NTLA-5001 (Intellia Therapeutics)
      • 14.4.5.6.1. Sales Forecast (USD Million)
      • 14.4.5.6.2. Net Present Value (USD Million)
      • 14.4.5.6.3. Value Creation Analysis
    • 14.4.5.7. TBI-1301 (Takara Bio)
      • 14.4.5.7.1. Sales Forecast (USD Million)
      • 14.4.5.7.2. Net Present Value (USD Million)
      • 14.4.5.7.3. Value Creation Analysis
    • 14.4.5.8. LMBP2-specific TCR-T (Xinqiao Hospital of Chongqing / TCR CURE Biopharma Technology)
      • 14.4.5.8.1. Sales Forecast (USD Million)
      • 14.4.5.8.2. Net Present Value (USD Million)
      • 14.4.5.8.3. Value Creation Analysis
    • 14.4.5.9. FH-MCVA2TCR (TCRCure Biopharma)
      • 14.4.5.9.1. Sales Forecast (USD Million)
      • 14.4.5.9.2. Net Present Value (USD Million)
      • 14.4.5.9.3. Value Creation Analysis

15. PROMOTIONAL ANALYSIS

• 15.1. Chapter Overview
• 15.2. Channels Used for Promotional Campaigns
• 15.3. Kimmtrak: Promotional Analysis
  • 15.3.1. Drug Overview
  • 15.3.2. Product Website Analysis
    • 15.3.2.1. Message for Healthcare Professionals
    • 15.3.2.2. Message for Patients
    • 15.3.2.3. Informative Downloads
  • 15.3.3. Patient Support Services

16. COMPANY PROFILES

• 16.1. Chapter Overview
• 16.2. Adaptimmune Therapeutics
• 16.3. Alaunos Therapeutics
• 16.4 Bluebird Bio
• 16.5. Bristol Myers Squibb
• 16.6. Cellular Biomedicine Group
• 16.7. Gilead Sciences
• 16.8. GlaxoSmithKline
• 16.9. Immatics
• 16.10. Immunocore
• 16.11. Lion TCR
• 16.12. Takara Bio
• 16.13. Zelluna immunotherapy

17. CONCLUDING REMARKS

18. EXECUTIVE INSIGHTS

• 18.1. Chapter Overview
• 18.2. Celyad
  • 18.2.1. Interview Transcript: Vice President, Immuno-Oncology
• 18.3. Kite Pharma
  • 18.3.1. Interview Transcript: Vice President, Scientific Affairs
• 18.4. Lion TCR
  • 18.4.1. Interview Transcript: Co-Founder and Chief Executive Officer
• 18.5. TxCell
  • 18.5.1. Interview Transcript: Chief Operating Officer

19. APPENDIX 1: TABULATED DATA

20. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

관련자료